Medicare Enrolled
Dr. Daniel Patterson, MD,PHD, MRCP,
Hematology & Oncology · Ocala, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Patterson from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Patterson?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Patterson
Dr. Daniel Patterson is a hematology & oncology specialist in Ocala, FL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Patterson performed 106,886 Medicare services across 3,009 unique beneficiaries.
Between the years covered by Open Payments, Dr. Patterson received a total of $35,086 from 68 pharmaceutical and/or device companies across 789 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Patterson is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 6% volume in FL
$35,086 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 80575 | Clear | January 31, 2028 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗106,886
Medicare services
Top 6% in FL for hematology & oncology
3,009
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,626 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
70,380 | $0 | $3 |
| Denosumab injection (Prolia/Xgeva) | 7,920 | $18 | $45 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
6,748 | $0 | $0 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
5,660 | $6 | $20 |
| Anti-nausea injection (ondansetron/Zofran) | 4,229 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
2,102 | $8 | $12 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
2,034 | $8 | $20 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,333 | $96 | $177 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
851 | $95 | $200 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
766 | $11 | $39 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
639 | $12 | $35 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
563 | $10 | $75 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
508 | $22 | $70 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
488 | $1 | $5 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
394 | $1 | $4 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
278 | $64 | $153 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
269 | $24 | $100 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
248 | $70 | $103 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
245 | $1 | $10 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
230 | $98 | $300 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
222 | $139 | $350 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
215 | $48 | $125 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
137 | $22 | $100 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
127 | $10 | $50 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
115 | $15 | $50 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
79 | $129 | $265 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
58 | $4 | $17 |
| Stool test for blood A laboratory test that checks a stool sample for hidden blood using a chemical reaction. This test helps detect bleeding in the digestive tract. |
27 | $4 | $16 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
21 | $138 | $225 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
67.3% high complexity
25.3% medium
7.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$35,086
Total received (2018-2024)
Avg $5,012/year across 7 years
Top 18% in FL for hematology & oncology
68
Companies
789
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$15,820 (45.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,577 (44.4%)
Other
Charitable contributions, space rental, and other categories
$2,770 (7.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$919 (2.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,521
2023
$2,547
2022
$3,202
2021
$3,094
2020
$1,298
2019
$17,579
2018
$2,845
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Celgene Corporation
$11,421
E.R. Squibb & Sons, L.L.C.
$5,094
Novartis Pharmaceuticals Corporation
$3,229
AstraZeneca Pharmaceuticals LP
$2,516
Lilly USA, LLC
$972
PFIZER INC.
$819
Amgen Inc.
$819
Astellas Pharma US Inc
$742
EMD Serono, Inc.
$664
Incyte Corporation
$648
Janssen Biotech, Inc.
$571
Foundation Medicine, Inc.
$568
Eisai Inc.
$523
Regeneron Healthcare Solutions, Inc.
$449
Seattle Genetics, Inc.
$429
Seagen Inc.
$427
JAZZ PHARMACEUTICALS INC.
$368
Merck Sharp & Dohme Corporation
$294
GENZYME CORPORATION
$287
Takeda Pharmaceuticals U.S.A., Inc.
$246
Daiichi Sankyo Inc.
$240
GlaxoSmithKline, LLC.
$235
Pharmacyclics LLC, An AbbVie Company
$217
Genentech USA, Inc.
$201
Sobi, Inc
$183
ASD SPECIALTY HEALTHCARE, LLC
$172
NOVARTIS PHARMACEUTICALS CORPORATION
$167
Rigel Pharmaceuticals, Inc.
$162
Karyopharm Therapeutics Inc.
$158
Boehringer Ingelheim Pharmaceuticals, Inc.
$148
EISAI INC.
$145
TOLMAR Pharmaceuticals, Inc.
$140
Dendreon Pharmaceuticals LLC
$135
Bayer HealthCare Pharmaceuticals Inc.
$119
PAINTEQ LLC
$104
Merck Sharp & Dohme LLC
$104
Teva Pharmaceuticals USA, Inc.
$102
SERVIER PHARMACEUTICALS LLC
$102
ABBVIE INC.
$100
Clovis Oncology, Inc.
$80
Octapharma USA, Inc.
$65
RECORDATI_RARE_DISEASES_INC.
$61
Ipsen Biopharmaceuticals, Inc
$60
PharmaEssentia USA Corporation
$59
Alexion Pharmaceuticals, Inc.
$50
Janssen Pharmaceuticals, Inc
$50
Novocure Inc.
$50
Tempus AI, Inc
$46
AVEO Pharmaceuticals, Inc.
$46
SUN PHARMACEUTICAL INDUSTRIES INC.
$41
TAIHO ONCOLOGY, INC.
$39
Bayer Healthcare Pharmaceuticals Inc.
$38
Agios Pharmaceuticals, Inc.
$38
Tolmar, Inc.
$36
Taiho Oncology, Inc.
$28
G1 Therapeutics, Inc.
$28
CSL Behring
$26
Abbott Laboratories
$26
Exelixis Inc.
$25
PUMA BIOTECHNOLOGY, INC.
$25
Sun Pharmaceutical Industries Inc.
$23
Aveo Pharmaceuticals, Inc.
$21
SHIELD THERAPEUTICS INC
$20
Partner Therapeutics, Inc.
$19
Pharmacosmos Therapeutics Inc.
$18
EUSA Pharma (US) LLC
$17
MorphoSys, US Inc.
$16
Gilead Sciences, Inc.
$12
Top 3 companies account for 56.3% of total payments
Associated products mentioned in payments ›
ABECMA · ACCRUFER · ADCETRIS · ALIMTA · Alecensa · Aliqopa · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · Bavencio · Blincyto · CABLIVI · CALQUENCE · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · ELIGARD · ELIQUIS · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · EVENITY · Enhertu · Erleada · FOTIVDA · FOUNDATIONONE · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Idelvion · Imbruvica · JADENU · JAKAFI · JAYPIRCA · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LUTATHERA · LYNPARZA · Lenvima · Leukine · Luspatercept · MEKINIST · MONJUVI · MVASI · NINLARO · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Odomzo · Optune · PADCEV · PAINTEQ · PANZYGA · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Padcev · Perjeta · Polivy · Pomalyst · Proclaim IPG · Prolia · REBLOZYL · RETEVMO · RYDAPT · Revlimid · Rezlidhia · Rubraca · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYLVANT · Somatuline Depot · Stivarga · Sylvant · TAFINLAR · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tibsovo · ULTOMIRIS · VELCADE · VENCLEXTA · VERZENIO · Vectibix · Vitrakvi · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · YONSA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (45%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $33 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
6
Per 100K population
1.5
County median income
$58,535
Nearest hospital
MARION COMMUNTIY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Patterson is a mixed practice specialist, with above-average Medicare volume (top 6% in FL), with consulting-driven industry engagement in the top 18% of FL peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Patterson experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Patterson performed 70,380 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Patterson receive payments from pharmaceutical companies?
Yes. Dr. Patterson received a total of $35,086 from 68 companies across 789 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Patterson's costs compare to other hematology & oncology specialists in Ocala?
Dr. Patterson's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Patterson) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Ocala
Browse hematology & oncology specialists in Ocala ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in FL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in FL
Which FL hematology & oncology specialists receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology